H.C. Wainwright analyst Brandon Folkes raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $121 from $93 and keeps a Buy rating on the shares. The firm says Cortrophin Gel script data continues to track ahead of its forecasts. In addition, the the addressable market for Cortrophin is larger larger previously modeled, with 500,000 acute gout flares offering a “very significant opportunity, along with multiple other indications,” the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals price target raised to $114 from $86 at Guggenheim
- ANI Pharmaceuticals Highlights Commercialization Focus Amid Challenges
- ANI Pharmaceuticals’ Record Earnings and Optimistic Outlook
- ANI Pharmaceuticals price target raised to $77 from $65 at Truist
- ANI Pharmaceuticals Reports Record Growth in Q2 2025